11/15/18 Ruxolitinib Moves On Without Me

I started the BATCC clinical trial on ruxolitinib on June 17, 2016. It was a two year trial designed test the effectiveness of ruxolitinib on alleviating the symptoms of CLL (fatigue, bone pain, joint pain, and others) by targeting cells that carried the JAK-7 enzyme, which produces inflammation. Inflammation is the source of many diseases…

5/12/18 Summer’s Here

No. It’s not really summer, yet, but today sure seemed like it. Summers seem harsher here than they used to be. Maybe my tolerance is faltering. Lots of things at my age are faltering. I am glad to be still be here. We have been working long hours in Olive Branch, Mississippi, in the throes…

4/15/18 Two More Years

I have been on the Ruxolitinib trial for two years now. It has been good so far. The trial was designed to address the symptoms of CLL and prove, disprove, or measure its efficacy in individual patients. The requirements of the trial were that each person enrolled must not be treatment naive, meaning that they…

2/12/18 Houston as the Gathering Place

It was just a simple Facebook post about being in Houston for my two month checkup. It was followed by a message from Tennessee’s husband, Sam. “We are here and would like to meet up if we can,” Sam wrote. That stopped me in my tracks. Tennessee and Sam and I have been Facebook friends…

2/1/17 A Trip into Decadence

Debbie and I made a trip to Houston on Sunday. I had an appointment at BATCC for my two month checkup for the Ruxolitinib clinical trial I am on. For a while we were making the trip every two weeks, but now, we have settled into two month, which is a lot better. Over the…

12/26/16 Nothing Profound

That’s what I wanted: to write something profound. Profundity as a goal is elusive, though it can overtake us unawares from time to time, which is probably the best sort of profundity: the unplanned. We all have it from time to time, and we mostly lack it when we are setting out to be profound.…